COVID-19 Drug Developer Joins IPO Pipeline In Packed Week
COVID-19-focused biotechnology firm Atea Pharmaceuticals Inc. set a price range Monday for an estimated $253 million initial public offering, one of two Latham-led drug developers to join a packed lineup of...To view the full article, register now.
Already a subscriber? Click here to view full article